Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient

Antimicrob Agents Chemother. 2015 Dec 31;60(1):1-5. doi: 10.1128/AAC.masthead.60-1. Print 2016 Jan.

Abstract

Respiratory infection with Burkholderia cenocepacia is associated with accelerated decline in lung function and increased mortality in cystic fibrosis (CF) patients (A. M. Jones, M. E. Dodd, J. R. W. Govan, V. Barcus, C. J. Doherty, J. Morris, and A. K. Webb, Thorax 59:948-951, 2004, http://dx.doi.org/10.1136/thx.2003.017210). B. cenocepacia often possesses innate resistance to multiple antimicrobial classes, making eradication uncommon in established infection (P. B. Davis, Am J Respir Crit Care Med 173:475-482, 2006, http://dx.doi.org/10.1164/rccm.200505-840OE). We report the use of clinafloxacin in a CF patient with advanced B. cenocepacia infection, present pharmacokinetic (PK) data, and discuss the potential therapeutic role of clinafloxacin in patients with this condition.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / pharmacokinetics
  • Burkholderia Infections / complications
  • Burkholderia Infections / drug therapy*
  • Burkholderia Infections / microbiology
  • Burkholderia Infections / pathology
  • Burkholderia cenocepacia / drug effects
  • Burkholderia cenocepacia / growth & development
  • Burkholderia cenocepacia / pathogenicity
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / microbiology
  • Cystic Fibrosis / pathology
  • Diabetes Complications
  • Diabetes Mellitus / microbiology
  • Diabetes Mellitus / pathology
  • Exocrine Pancreatic Insufficiency / complications
  • Exocrine Pancreatic Insufficiency / microbiology
  • Exocrine Pancreatic Insufficiency / pathology
  • Fatal Outcome
  • Fluoroquinolones / administration & dosage*
  • Fluoroquinolones / pharmacokinetics
  • Humans
  • Lung / drug effects
  • Lung / microbiology
  • Lung / pathology
  • Male
  • Pseudomonas Infections / complications
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / microbiology
  • Pseudomonas Infections / pathology
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / growth & development
  • Pseudomonas aeruginosa / pathogenicity
  • Treatment Failure

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • clinafloxacin